| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | Director | Stock Option (right to buy) | 1,950,000 | 22 Jun 2023 | Direct | ||
| Gossamer Bio, Inc. | Director | Stock Option (Right to Buy) | 115,000 | 25 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | 25 Jun 2025 | 1 | $0 | 4 | Director | 26 Jun 2025, 16:38 |
| GOSS | Gossamer Bio, Inc. | 06 Jun 2024 | 1 | $0 | 4 | Director | 06 Jun 2024, 21:58 |
| SYRE | Aeglea BioTherapeutics, Inc. | 22 Jun 2023 | 1 | $0 | 4 | Director | 30 Jun 2023, 16:33 |
| GOSS | Gossamer Bio, Inc. | 08 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 16:15 |
| GOSS | Gossamer Bio, Inc. | 09 Jun 2022 | 1 | $0 | 4 | Director | 15 Jul 2022, 17:06 |
| SYRE | Aeglea BioTherapeutics, Inc. | 07 Jun 2022 | 1 | $0 | 4 | Director | 09 Jun 2022, 21:13 |
| GOSS | Gossamer Bio, Inc. | 09 Jun 2021 | 1 | $0 | 4 | Director | 10 Jun 2021, 19:49 |
| SYRE | Aeglea BioTherapeutics, Inc. | 08 Jun 2021 | 1 | $0 | 4 | Director | 09 Jun 2021, 17:23 |